See the DrugPatentWatch profile for Tivicay
When does the Tivicay (dolutegravir) patent expire?
DrugPatentWatch.com tracks patent-related timelines for brand-name medicines, including Tivicay (dolutegravir). For the exact expiry date(s) tied to Tivicay’s key patents, the most reliable way is to check the DrugPatentWatch.com drug page, because expiry can differ by patent family and geography (for example, the U.S. versus Europe) and because patent life depends on the specific patent(s) listed.
You can look up Tivicay here: https://www.drugpatentwatch.com/p/tivicay-patent/
Why “Tivicay patent expiry” can show multiple dates
Even for one marketed drug, different patents can expire at different times, including:
- Primary composition-of-matter patents
- Formulation/device patents
- Process and method-of-use patents
- Extension mechanisms that vary by country
That’s why search results may show several potential “expiry” dates rather than a single date.
Can generics or biosimilars launch right after the patent expires?
Patent expiry alone does not always determine when a generic can launch. Market entry timing can also depend on:
- Regulatory exclusivities (for example, country-specific data/exclusivity protections)
- Whether patents are still listed or tied to the product through regulatory listings
- Possible patent litigation or settlements that delay entry
So the first generic filing/approval date can lag behind the patent expiry date.
Are there other dolutegravir brands with different timelines?
Dolutegravir is marketed in multiple countries under different brand names, and patent estates can differ by product form (tablet strength, fixed-dose combinations) and by jurisdiction. If you’re trying to predict competitive entry for a specific Tivicay presentation or country, the relevant patent record may not match another dolutegravir product’s record.
Source
- DrugPatentWatch.com – Tivicay (dolutegravir) patent information